Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells

23 Feb 2021

Abstract excerpt

Recently, a rare type of relapse was reported upon treating a B cell acute lymphoblastic leukemia (B-ALL) patient with anti-CD19 chimeric antigen receptor (CAR)-T cells caused by unintentional transduction of residual malignant B cells (CAR-B cells). We show that anti-CD19 and anti-CD20 CARs are presented on the surface of lentiviral vectors (LVs), inducing specific binding to the respective antigen. Binding of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33768128
DOI: 10.1016/j.omtm.2021.02.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cellsPMID 33768128Read ↗

Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospectsSemantic proximity Read ↗

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndromeSemantic proximity Read ↗

Establishment of a simple and efficient platform for car-t cell generation and expansion: from lentiviral production to in vivo studiesSemantic proximity Read ↗

Lentiviral Vectors for CAR-T and Other Cell Therapy Products: A Microbiological and Biosafety PerspectiveSemantic proximity Read ↗

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read ↗

Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CARSemantic proximity Read ↗

In Vivo Generation of CAR T Cells Selectively in Human CD4+ LymphocytesSemantic proximity Read ↗

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.Semantic proximity Read ↗

Overcoming the challenges of primary resistance and relapse after CAR-T cell therapySemantic proximity Read ↗

Large Scale In-House Point-of-Care Manufacturing of Clinical Grade Autologous Anti-CD19 CAR T Cells in Saudi ArabiaSemantic proximity Read ↗

Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-T <sub>SCM</sub> cells using <i>qCART</i> , the <i>Quantum pBac</i> -based CAR-T systemSemantic proximity Read ↗

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.